FDA approves Roche's Cotellic for combination skin cancer therapy

ZURICH (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Swiss drugmaker Roche's Cotellic to be used in combination with the company's Zelboraf drug to treat BRAF V600 mutation-positive advanced melanoma.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Abstract The field of cancer immunology stepped into the limelight this year when James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation. Among many exciting advances contributing to the coming of age of tumour immunology as a viable clinical specialty has been the ability to progress from the initial elucidation of tumour antigens, such as the melanoma antigen, MAGE-1, to high-throughput sequencing facilitating identification of T cell epitopes from diverse tumour neoantigens. This has resulted from the...
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
In conclusion, targeting miRNAs through antisense oligonucleotides technology may suggest the way to enhance the action of BRAF-inhibitors.
Source: IEEE/ACM Transactions on Computational Biology and Bioinformatics - Category: Bioinformatics Source Type: research
CONCLUSIONS: These results support the clinical use of consensus MAGE-A immunogens with the capacity to target multiple MAGE-A family members to prevent tumor immune escape. PMID: 30262507 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
LOS ANGELES– Stand Up To Cancer (SU2C), a division of the Entertainment Industry Foundation (EIF), is proud to announce that the Hollywood community is rallying together yet again to support the sixth biennial televised fundraising special. CBS will donate one hour of commercial-free primetime to broadcast the event on Friday, Sept. 7  from 8:00 – 9:00 PM ET/PT (7:00 – 8:00 PM CT). Mahershala Ali, Kathy Bates, Katie Couric, Jennifer Garner, Tony Hale, Marg Helgenberger, Ed Helms, Ken Jeong, Marlee Matlin, Matthew McConaughey, Maria Menounos, Jillian Michaels, Trevor Noah, Dak Prescott, Italia Ricci, ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Only CBS Stand Up To Cancer Source Type: news
Cancer treatment has been transformed by the use of monoclonal antibodies (mAbs) that block immune inhibitory ligands CTLA-4 and PD-1, known as immune checkpoint inhibitors (CPIs). With these options for treatment of cancers that are resistant to conventional cancer therapies, the life expectancy of patients with melanoma, lung cancer, renal cell carcinoma, and other cancers, has shown significant improvement. However, according to the journal Diabetes, some patients experience adverse effects. One percent of patients treated with anti –PD-1 or –PD-L1 CPIs develop diabetes.08/22/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
CONCLUSION: This approach merging qualitative and quantitative data suggests that mMCC patients report a better experience with avelumab than with chemotherapy. PMID: 30107762 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
We report on combination effects of these two promising strategies. Tumor targeting 131I-labelled anti-EGFR-antibody (Cetuximab) was used in the prototypic EGFR-expressing A431 human squamous cell carcinoma xenograft model. A 131I-labelled melanin-binding benzamide derivative was utilized targeting B16F10 melanoma in an orthotopic syngeneic C57bl6 model. Fractionated EBRT was performed using carbon ions in direct comparison with conventional photon irradiation. Tumor uptake of 131I-Cetuximab and 131I-Benzamide was enhanced by fractionated EBRT as determined by biodistribution studies. This effect was independent of radiati...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: 1 October 2018Source: Colloids and Surfaces B: Biointerfaces, Volume 170Author(s): M. Gorgizadeh, N. Azarpira, N. SattarahmadyAbstractNanothechnology-mediated photothermal therapy (PTT) is emerging as one of the inspiring alternative modality of cancer therapy that applies near-infrared radiation. High favorability of this approach is due to its minimum invasiveness, safety of non-targeted area, quick recovery, and capable simultaneous imaging. In this approach, photoabsorbing nanomaterials convert energy of infrared light to vibrational motion and generate heat. In the present study, a nanocomposite comp...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
ConclusionWe report the clinical and genomic landscape of a patient with MPTs who had no identifiable unique somatic or germline mutations to explain her predilection to cancer. The treatment course and overall prognosis for this patient is important for understanding future cases with unrelated, metachronous MPTs, the occurrence of which cannot always be explained by underlying genetic mechanisms.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Health | Melanoma | Skin | Skin Cancer